Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-4681
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy ; volume:26 ; number:13 ; day:26 ; month:8 ; year:2019 ; pages:4274-4283 ; date:12.2019
Annals of surgical oncology ; 26, Heft 13 (26.8.2019), 4274-4283, 12.2019
- Creator
-
Müller, Hannah Deborah
Posch, Florian
Suppan, Christoph
Bargfrieder, Ute
Gumpoldsberger, Melanie
Hammer, Robert
Hauser, Hubert
Dandachi, Nadia
Prein, Kurt
Stoeger, Herbert
Lax, Sigurd
Balic, Marija
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-019-07741-w
- URN
-
urn:nbn:de:101:1-2020031617512765993278
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Müller, Hannah Deborah
- Posch, Florian
- Suppan, Christoph
- Bargfrieder, Ute
- Gumpoldsberger, Melanie
- Hammer, Robert
- Hauser, Hubert
- Dandachi, Nadia
- Prein, Kurt
- Stoeger, Herbert
- Lax, Sigurd
- Balic, Marija
- SpringerLink (Online service)
Other Objects (12)
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Vacuum-Assisted Breast Biopsy After Neoadjuvant Systemic Treatment for Reliable Exclusion of Residual Cancer in Breast Cancer Patients
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Neoadjuvant chemotherapy weakens the prognostic value of the pathological tumor burden score for colorectal cancer liver metastases
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer
Correction: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues